Evidence map›Paper›PMID 42278569›Full record

ArticleInternational journal of molecular sciences2026

rRGD3

Qianhui Yuan, Fuxin Zhou, Xiaotong Li, Jingyu Zhang, Yuebin Zhang, Jihong Yao, Mei Lv, Jihong Wang, Li Lv

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qianhui YuanDepartment of Pharmacology, Dalian Medical University, Dalian 116044, China.
Fuxin ZhouDepartment of Pharmacology, Dalian Medical University, Dalian 116044, China.
Xiaotong LiDepartment of Pharmacology, Dalian Medical University, Dalian 116044, China.
Jingyu ZhangSchool of Life Sciences, Liaoning Normal University, Dalian 116081, China.
Yuebin ZhangSchool of Life Sciences, Liaoning Normal University, Dalian 116081, China.
Jihong YaoDepartment of Pharmacology, Dalian Medical University, Dalian 116044, China.
Mei LvDepartment of Otorhinolaryngology and Head and Neck Surgery, Dalian Medical University, Dalian 116100, China.
Jihong WangSchool of Life Sciences, Liaoning Normal University, Dalian 116081, China.
Li LvDepartment of Pharmacology, Dalian Medical University, Dalian 116044, China.ORCID 0009-0001-6166-2783

Funding

Educational Department of Liaoning Province LJKFZ20220251
6 · The paper itself

Abstract

Nasopharyngeal carcinoma-associated malignant epithelial models remain useful for exploring integrin-related therapeutic strategies. In this study, we evaluated the antitumor activity and potential mechanisms of rRGD3

Indexed as

Integrin beta1Nasopharyngeal CarcinomaNasopharyngeal NeoplasmsOligopeptidesSignal TransductionAmino Acid SequenceAnimalsApoptosisCell Line, TumorEpithelial-Mesenchymal TransitionFocal Adhesion Kinase 1HumansMaleMiceMice, Inbred BALB CProto-Oncogene Proteins c-aktarginyl-glycyl-aspartic acidFocal Adhesion Kinase 1Integrin beta1Itgb1 protein, humanOligopeptidesProto-Oncogene Proteins c-aktRecombinant ProteinsapoptosisEMTFAK/AKT axisintegrin β1nasopharyngeal carcinomarecombinant peptiderRGD3mu

Identifiers

PMID42278569
PMCPMC13256499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.